MKI67 and neoplasm: Results Among abemaciclib-eligible patients (36.2%, n=121), 54.5% had ≥4 positive nodes, and 45.5% met alternative high-risk criteria (1-3 nodes plus tumor size of ≥5 cm or grade 3 or Ki-67 of ≥20%). Ribociclib-eligible patients (59%, n=197) included 53.8% with stage III disease and 12.7% with node-negative, grade 3 tumors.